Donate today to support women in science at Burnet and their work to unlock the vaginal microbiome and reduce risk of HIV infection and preterm birth for women around the world.
Improving the health of vulnerable communities and changing lives is at the heart of what we do and who we are.
The Australian Trial in Acute Hepatitis C (ATAHC) was an NIH-funded multicentre prospective cohort study of the natural history, and outcomes following treatment with PEG (with or without RBV) in individuals with acute and early chronic HCV infection.
The final results were published in the journal Gastroenterology19.
Between 2004 and 2008, 167 subjects with acute and early chronic HCV infection were enrolled throughout Australia, of whom 111 (76%) subjects with detectable HCV RNA at screening elected to undertake treatment.
the median estimated duration of infection was 25 weeks, indicating that around half the patients had early chronic HCV infection.
33% of subjects were HIV co-infected.
Final analysis of treatment outcomes in the 74 HCV mono-infected subjects who commenced treatment with PEG monotherapy demonstrate: - SVR rates of 55% by intention-to-treat - 72% per-protocol analysis.
For any general enquiries relating to this project, please contact:
Research Officer
To create and translate knowledge into better health, so no-one is left behind.
85 Commercial Road, Melbourne
VIC, 3004, Australia
Receive updates and IMPACT magazine.
Copyright © 2023 Burnet Institute. ABN: 49 007 349 984
This website was developed with the generous support of a donor.
Burnet Institute (Australia) is located on the traditional land of the Boon Wurrung people and we offer our respects to their Elders past and present.
We recognise and respect the continuation of cultural, spiritual and educational practices of Aboriginal and Torres Strait Islander peoples of this land.
